Microdosing with psychedelics is gaining popularity on a large scale, especially in the Netherlands. A few years ago it was introduced as a novel way to increase focus and creativity levels. Nowadays, many people have found in microdosing a powerful tool to alleviate depression. Others argue that it helps with PMS, mood swings, ADHD, and even cluster headaches.
On 26 May, Microdosing.nl invites scientists and specialists on stage to share what is known and to explore new grounds.
This second MICRODOSING SEMINAR is the only seminar dedicated exclusively to microdosing psychedelics. It facilitates an open space where the fast-growing microdosing community shares knowledge, maps the unknown and collectively looks forward.
The framework in which this seminar takes place is that of safe and responsible use of microdosing psychedelics. Microdosing.nl joins associations like MAPS, the Beckley Foundation and Dr. James Fadiman in their mission to explore the long-lasting benefits of psychedelics in both patients and well people, which may have a positive impact on our society as a whole.
What to expect?
This all-afternoon event focuses on the practice of microdosing psychedelics and current research findings. Special attention goes to “facts versus fantasy” and microdosing as a holistic tool for personal leadership and transformation.
This seminar promises to be an inspiring gathering for the fast-growing circle of enthusiastic researchers, psychologists, coaches, harm-reduction professionals and those who intend to discover microdosing on an experiential level. No matter what’s your background or experience, this is going to be a unique opportunity to connect, share and enrich your knowledge.
Meet everyone in this fresh circle and join the conversation!
On the program
James Fadiman, Ph.D. (via Skype)
Might microdosing psychedelics be safe and beneficial?
We open the seminar with a warm word of welcome from Dr. Fadiman. We also speak with him about his recent study amongst 1800+ microdosers from across the Western world, who reported fascinating, unexpected results. Besides discussing these results, Dr. Fadiman speaks about safety and contra-indications, further research into microdosing and possible future medical applications.
James Fadiman did his undergraduate work at Harvard and his graduate work at Stanford, doing research with the Harvard Group, the West Coast Research Group in Menlo Park, and Ken Kesey. He is the author of The Psychedelic Explorer’s Guide. Called “America’s wisest and most respected authority on psychedelics and their use,” Jim Fadiman has been involved with psychedelic research since the 1960s. In this episode, we discuss the immediate and long-term effects of psychedelics when used for spiritual purposes (high dose), therapeutic purposes (moderate dose), and problem-solving purposes (low dose). Fadiman outlines best practices for safe “entheogenic” voyages learned through his more than 40 years of experience–from the benefits of having a sensitive guide during a session (and how to be one) to the importance of the setting and pre-session intention.
Toby Lea, Ph.D. German Institute for Addiction and Prevention Research, Centre for Social Research in Health, UNSW Sydney
Microdosing psychedelics: motivations, perceived health outcomes and harm reduction
This presentation will report findings from the Psychedelic Experiences Survey, an international online study of psychedelic use. This presentation will focus on more than 1000 people who reported microdosing experience and will examine microdosing motivations, short-term perceived benefits, and unwanted effects, harm reduction practices and perceived health outcomes.
Toby Lea is a Humboldt Foundation Research Fellow at the German Institute for Addiction and Prevention Research, Cologne, and an Adjunct Lecturer at the Centre for Social Research in Health, UNSW Sydney, Australia. He conducts applied social health research on the use of psychedelics as novel therapies for mental health, as well as research on substance use and harm reduction among sexual and gender minority people.
Kim Kuypers, Ph.D. University of Maastricht
Cognitive and Emotional Impact of Microdoses of LSD
Microdosing (MD) with psychedelics has gained considerable attention and visibility in the media, where it is portrayed as a performance and creativity enhancing means especially popular on the work floor. While reports are in general positive, scientific evidence on the potential negative effects is lacking aside from the prevalence and motives to use. In addition, next to the anecdotal reports on beneficial effects attributed to microdosing it is not clear whether these effects are due to users’ expectancy or truly induced by the substance and quantifiable by means of lab measures. To address the aforementioned gaps we’ve set up two studies, an online survey to gain insight in the dosing schedule, motivation and potential experienced negative effects of microdosing and a placebo-controlled experimental study to assess the acute effects of LSD microdosing. In my talk, I will discuss the findings and associated implications in relation to potential therapeutic applications.
Kim Kuypers works as an assistant professor at Maastricht University. Her research focusses on understanding the neurobiology underlying creativity, empathy and well-being. To accomplish this she uses a psychopharmacological model, studying the acute, subacute and longer lasting effects of psychedelics on these behaviors and biology. The generated knowledge can be used to enhance flexible thinking and social abilities in the daily life of pathological populations and consequently enhancing their quality of life and feelings of wellbeing.
Hein J. Hendrik Co-founder Microdosing.nl
A realistic view on microdosing psychedelics
Since the start of Microdosing.nl we have heard the same claims and easy conclusions about the effects of microdosing over and over again. It will make you more creative and work harder and more efficient. Rings a bell? How much of this is true? And which common, relevant effects are not (yet) highlighted by the media? in his talk, Hein compares the popular misconceptions with actual first-hand experiences from microdosers, including those in our Microdosing.nl community.
David Valkenburg Independent researcher
Getting started with microdosing
In his presentation, David will guide those who are relatively new to microdosing through the decision process on 1) whether to microdose or not 2) with which substance to microdose, including the differences between several psychedelics specifically catered to the practice of microdosing 3) which schedules/user protocols exist and how to find out which one works best for you and 4) how to stay safe and comfortable during your microdosing experiment.
Jakobien van der Weijden Co-founder Microdosing.nl
A holistic approach to microdosing
How to get the most out of your microdosing practice? Jakobien will present a possible approach on how to use microdosing as a tool to support your personal development. What if the key element is YOU, not the microdoses you are taking? Combining research findings and therapist’s reports from the fields of psychedelics-assisted-therapy, neuroscience and holistic counselling, she makes the case of how our mind, body and soul are not separated and that they can, when working properly together, rebalance your system. Jakobien explores how microdosing might support this mechanism of selfhealing, or self empowerment, and how you can use this to your benefit.
Panel discussion and Q&A
with Kim Kuypers, Toby Lea, Josi Marschall, Jakobien van der Weijden and Hein J. Hendrik. Moderated by David Valkenburg.
All the other details
26 May 2019
doors open 14.30
programme 15.00 – 19.00
drinks from 19.00
Reserve your seat
€ 22,50 early bird
€ 27,50 regular
€ 50 support our mission ticket
Coffee, tea and snacks are included
How to get there?
Mirror Centre is in front of Muiderpoort station (exit Indische buurt)
Coming by car? Parking in the neighbourhood of Mirror Centre is limited (free on Sundays). QPark Oostpoort is a good alternative, it’s only a 5 minute walk.